Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PON1 | P27169 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30831856 | 1.00 | PON1 (0.36) | PON1SLC6A4TAAR1IDO1SLC6A2 | |
| SCHEMBL9984918 | 0.82 | SLC6A4 (0.44) | SLC6A4TAAR1SLC6A2KMT2A | |
| SCHEMBL21768186 | 0.82 | IDO1 (0.37) | PON1SLC6A4IDO1SLC6A2KMT2A | |
| SCHEMBL15121002 | 0.79 | KIF11 (0.36) | SLC6A4TAAR1 | |
| SCHEMBL27804944 | 0.79 | TAAR1 (0.34) | SLC6A4TAAR1IDO1SLC6A2 | |
| SCHEMBL15654574 | 0.78 | IDO1 (0.41) | SLC6A4IDO1SLC6A2 | |
| SCHEMBL26586486 | 0.77 | TAAR1 (0.33) | SLC6A4TAAR1 | |
| SCHEMBL14497651 | 0.77 | TAAR1 (0.33) | SLC6A4TAAR1IDO1 | |
| SCHEMBL8194043 | 0.76 | IDO1 (0.35) | IDO1 | |
| SCHEMBL1030033 | 0.76 | TAAR1 (0.56) | PON1TAAR1KMT2ANPSR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110536885-B | Process for producing difluoromethylene compound | 佐藤制药株式会社 | 2024-03-08 | — | — | CN | disclosed |
| US-11084792-B2 | Method for producing difluoromethylene compound | SATO PHARMACEUTICAL CO., LTD. (JP) | 2021-08-10 | — | — | US | disclosed |
| US-20200190038-A1 | METHOD FOR PRODUCING DIFLUOROMETHYLENE COMPOUND | SATO PHARMACEUTICAL CO., LTD. (JP) | 2020-06-18 | — | — | US | disclosed |
| EP-3617197-A1 | METHOD FOR PRODUCING DIFLUOROMETHYLENE COMPOUND | Sato Pharmaceutical Co., Ltd. (JP) | 2020-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190038-A1 | METHOD FOR PRODUCING DIFLUOROMETHYLENE COMPOUND | HACL2, MGLL, ABL1 | PON1 734/4885SLC6A4 4477/4885TAAR1 220/4885 |
| US-11084792-B2 | Method for producing difluoromethylene compound | HACL2, MGLL, ABL1 | PON1 734/4885SLC6A4 4477/4885TAAR1 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.